tbuckley/cabot-search huggingface dataset:
Risco residual de infecções virais transmitidas pelo sangue na Espanha, 1997-2002, e impacto do teste de ácidos nucleicos (NAT)
Authors: M Alvarez do Barrio, R González Díez, J M Hernández Sánchez, S Oyonarte Gómez
Journal: Eurosurveillance (2005)

As estimacoes do risco de infeccoes virais transmitidas por transfusao de sangue sao essenciais para evaluar a seguranca dos componentes do sangue e o impacto de novos testes de rastreio. Entre 1997 e 1999 foram calculadas as taxas de incidencia de seroco
The rise of the opioid epidemic and hepatitis C–positive organs: A new era in liver transplantation
Authors: Stevan A. Gonzalez, James F. Trotter
Journal: Hepatology (2017)

The use of hepatitis C virus (HCV)‐positive organs in liver transplantation (LT) has increased in the era of direct‐acting antiviral therapy. A rising demand for organs, the increased ability to effectively treat HCV infection in the transplant setting, and an unprecedented increase in HCV‐positive donors have all contributed to this trend. A recent abrupt rise in opioid use in the United States has resulted in a surge of injection drug use, transmission of HCV, and opioid‐related overdose deaths. Geographical areas most affected by the opioid epidemic have experienced a rapid increase in recovery and utilization of HCV‐positive donor organs, in which the proportion of deceased donor LTs in the United States from donors who are HCV positive has increased nearly 2‐fold within the last 3 years. The prospect of expanding the organ donor pool with HCV‐positive donors and achieving acceptable posttransplant outcomes has generated much interest in the areas of liver, kidney, and thoracic transplantation, including the potential for transplanting organs from HCV positive donors into HCV‐negative recipients. Developing strategies to ensure appropriate selection of potential recipients of HCV‐positive organs, initiating timely antiviral therapy, and defining associated risks will be critical in achieving optimal posttransplant outcomes in this setting. (Hepatology 2018;67:1600‐1608).
A Collaborative Model for Accelerating the Discovery and Translation of Cancer Therapies
Authors: Ophélia Maertens, Mila E. McCurrach, Benjamin S. Braun, Thomas De Raedt, Inbal Epstein, Tannie Q. Huang, Jennifer O. Lauchle, Hyerim Lee, Jianqiang Wu, Timothy P. Cripe, D. Wade Clapp, Nancy Ratner, Kevin Shannon, Karen Cichowski
Journal: Cancer Research (2017)

Preclinical studies using genetically engineered mouse models (GEMM) have the potential to expedite the development of effective new therapies; however, they are not routinely integrated into drug development pipelines. GEMMs may be particularly valuable for investigating treatments for less common cancers, which frequently lack alternative faithful models. Here, we describe a multicenter cooperative group that has successfully leveraged the expertise and resources from philanthropic foundations, academia, and industry to advance therapeutic discovery and translation using GEMMs as a preclinical platform. This effort, known as the Neurofibromatosis Preclinical Consortium (NFPC), was established to accelerate new treatments for tumors associated with neurofibromatosis type 1 (NF1). At its inception, there were no effective treatments for NF1 and few promising approaches on the horizon. Since 2008, participating laboratories have conducted 95 preclinical trials of 38 drugs or combinations through collaborations with 18 pharmaceutical companies. Importantly, these studies have identified 13 therapeutic targets, which have inspired 16 clinical trials. This review outlines the opportunities and challenges of building this type of consortium and highlights how it can accelerate clinical translation. We believe that this strategy of foundation-academic-industry partnering is generally applicable to many diseases and has the potential to markedly improve the success of therapeutic development. Cancer Res; 77(21); 5706-11. ©2017 AACR.
KEYNOTE-522: Phase III study of pembrolizumab (pembro) + chemotherapy (chemo) vs placebo + chemo as neoadjuvant followed by pembro vs placebo as adjuvant therapy for triple-negative breast cancer (TNBC)
Authors: P. Schmid, J. Cortes Castan, J. Bergh, L. Pusztai, C. Denkert, S. Verma, H.L. McArthur, J. Zhao, G. Aktan, T. Dang, R. Dent
Journal: Annals of Oncology (2017)
Precision systems medicine in urological Tumors – Molecular profiling and functional testing
Authors: K. Saeed, P. Ojamies, T. Pellinen, V. Rahkama, S. Eldfors, L. Paavolainen, R. Turkki, P. Horvath, J. Lundin, H. Nisen, T.M. af Hällström, A. Rannikko, T. Mirtti, O. Kallioniemi, P. Östling
Journal: Annals of Oncology (2017)
Magnitude of clinical benefit of randomized controlled trials supporting US Food and Drug Administration approval of drugs for solid tumours
Authors: C. Molto Valiente, E. Amir, A. Ocana Fernandez, A. Templeton, L. del Carpio Huerta, J. Del Paggio, A. Barnadas, C. Booth, A. Tibau
Journal: Annals of Oncology (2017)
CD16-IL15-CD33 Trispecific Killer Engager (TriKE) Overcomes Cancer-Induced Immune Suppression and Induces Natural Killer Cell-Mediated Control of MDS and AML Via Enhanced Killing Kinetics
Authors: Martin Felices, Dhifaf Sarhan, Ludwig Brandt, Karolin Guldevall, Ron McElmurry, Alexander Lenvik, Sami Chu, Jakub Tolar, Elizabeth Taras, Stephen R Spellman, Erica D. Warlick, Michael R. Verneris, Sarah Cooley, Daniel Weisdorf, Bruce R. Blazar, Bjorn Onfelt, Dan Vallera, Jeffrey S. Miller
Journal: Blood (2016)
A phase IIa study of tisotumab vedotin (HuMax®-TF-ADC) in patients with relapsed, recurrent and/or metastatic cervical cancer
Authors: I. Vergote, E. Dean, U. Lassen, J. de Bono, Y. Drew, J-P. Machiels, D. Nielsen, H-T. Arkenau, M. Forster, R. Jones, B. Slomovitz, J. Spicer, M. Johnson, N. Cornez, C. Gennigens, B. Fulton, S. Lisby, L. Basse, R. Coleman, D.S. Hong
Journal: Annals of Oncology (2017)
Safety analysis of phase Ib study of FOLFOXIRI plus ramucirumab as first-line therapy for patients with metastatic colorectal cancer
Authors: H. Taniguchi, Y. Kito, H. Satake, Y. Horie, T. Yamada, T. Esaki, T. Denda, K. Mori, K. Yamazaki
Journal: Annals of Oncology (2017)
Urothelial Carcinoma of the Bladder and the Rise of Immunotherapy
Authors: David D. Chism
Journal: Journal of the National Comprehensive Cancer Network (2017)

With the advent of platinum-based chemotherapy, survival rates for metastatic urothelial carcinoma have plateaued, giving way to the modern immunotherapy paradigm. Although immunotherapy as an effective treatment dates back to the live, attenuated bacillus Calmette-Guérin vaccine, the recent impact of immune checkpoint inhibitors targeting programmed death/programmed death-ligand 1 (PD-1/PD-L1) coupled with the promise of both anti–cytotoxic T-lymphocyte–associated protein 4 (CTLA-4) antibodies and indoleamine-2, 3-dioxygenase-1 (IDO-1) inhibitors have provided a resurgence. To date, pembrolizumab, a PD-1 inhibitor, has been granted full FDA approval based on its high antitumor activity, tolerability, and efficacy, with notable prolonged durable responses in the second-line setting. Nivolumab (a PD-1 inhibitor) and atezolizumab, durvalumab, and avelumab (PD-L1 inhibitors) have also gained accelerated drug approval in the second-line setting. In addition, atezolizumab and pembrolizumab have been approved for platinum-ineligible patients in the first-line setting. Effective 2-drug combinations reported include nivolumab plus the CTLA-4 antibody ipilimumab and pembrolizumab plus the IDO-1 inhibitor epacadostat. Further expansion of immunotherapy will hinge in part on the ability to define responders versus nonresponders through the use of biomarkers like PD-L1 or mutational load. Clinical trials with immunotherapy for metastatic disease as single agents or in combination are ongoing. This review explores the rise of immunotherapy and presents the current treatments and challenges posed with development of biomarkers, and provides a summary of ongoing phase III clinical trials.
Safety and Efficacy of Niraparib in Elderly Patients (Pts) with Recurrent Ovarian Cancer (OC)
Authors: M. Fabbro, K.N. Moore, A. Dørum, A.V. Tinker, S. Mahner, I. Bover, S. Banerjee, G. Tognon, F. Goffin, R. Shapira-Frommer, R.M. Wenham, K. Hellman, D.M. Provencher, P. Harter, I. Palacio Vázquez, P. Follana, M.J. Pineda, M.R. Mirza, S.J. Hazard, U.A. Matulonis
Journal: Annals of Oncology (2017)
A Question of Social Justice: How Policies of Profit Negate Engagement of Developing World Bioethicists and Undermine Global Bioethics
Authors: Subrata Chattopadhyay, Catherine Myser, Tiffany Moxham, Raymond De Vries
Journal: The American Journal of Bioethics (2017)

We identify the ways the policies of leading international bioethics journals limit the participation of researchers working in the resource-constrained settings of low- and middle-income countries (LMICs) in the development of the field of bioethics. Lack of access to essential scholarly resources makes it extremely difficult, if not impossible, for many LMIC bioethicists to learn from, meaningfully engage in, and further contribute to the global bioethics discourse. Underrepresentation of LMIC perspectives in leading journals sustains the hegemony of Western bioethics, limits the presentation of diverse moral visions of life, health, and medicine, and undermines aspirations to create a truly "global" bioethics. Limited attention to this problem indicates a lack of empathy and moral imagination on the part of bioethicists in high-income countries, raises questions about the ethics of bioethics, and highlights the urgent need to find ways to remedy this social injustice.
Effects of painting art therapy on quality of life and depression in cancer patients—A comparative study.
Authors: Hakan Sat Bozcuk, Keziban Ozcan, Cengiz Erdoğan, Hasan Mutlu, Hasan Senol Coskun
Journal: Journal of Clinical Oncology (2014)

e17583 Background: There is limited data on the role of art therapy used in cancer patients. We wanted to see the effect of painting art therapy provided by a dedicated professional painting artist on quality of life and anxiety and depression levels in patients having chemotherapy. Methods: Cancer patients having chemotherapy in the day unit of a medical oncology department of a university hospital were offered to take part in a painting art therapy program (PATP). This program consisted of a professional painting artist facilitating and helping patients to perform painting during their chemotherapy sessions while they were in the day unit, as well as supplying them painting material for home practice. The changes in quality of life domains of EORTC-QLQ-C30 questionnaire and in Hospital Anxiety and Depression Scores (HADS) were assessed before and after the PATP. These results were contrasted with a reference group of cancer patients on chemotherapy but not taking part in the PATP. In order to adjust for multiple comparisons of quality of life parameters between patient groups, we utilized the Bonferroni correction. Results: A total of 48 patients, of which 26 patients did and 22 did not have prior exposure to PATP, were enrolled in the PATP. A control group of 24 patients who did not have any PATP activity during the study period also took part in the study. With PATP, there was significant improvement in global quality of life (F=7.87, P=0.001), and depression scores (F=7.80, P=0.001). Conclusions: To our knowledge, this is the largest comparative PATP experience in cancer patients on chemotherapy and show that PATP is feasible in the clinics. Our results confirm that art therapy in the form of painting improves quality of life and depression in cancer patients having chemotherapy. This effect was more pronounced in patients without any previous experience of PATP.
Paneth Cells in Carcinomas of the Small Intestine in a Mouse and in a Rat
Authors: Thelma B. Dunn, Albert M. Kessel
Journal: JNCI Journal of the National Cancer Institute (1945)

Journal Article Paneth Cells in Carcinomas of the Small Intestine in a Mouse and in a Rat Get access Thelma B. Dunn, Thelma B. Dunn research fellow in pathology National Cancer Institute, National Institute of Health, United States Public Health Service Search for other works by this author on: Oxford Academic PubMed Google Scholar Albert M. Kessel Albert M. Kessel senior medical technician National Cancer Institute, National Institute of Health, United States Public Health Service Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 6, Issue 2, October 1945, Pages 113–118, https://doi.org/10.1093/jnci/6.2.113 Published: 01 October 1945
Comparison of performances of three technologies for detection of RAS mutations in cfDNA (NGS strategy, BEAMing assay and ddPCR BioRAD assay)
Authors: J. Garcia, J. Forestier, E. Dusserre, C. Rodriguez-Lafrasse, V. Cheynet, A.S. Wosny, C. Ferraro Peyret, K. Brengel-Pesce, M. Guillet, M. Chauvenet, S. Couraud, M. Brevet, T. Walter, L. Payen
Journal: Annals of Oncology (2017)
BCG en Finlandia : cambio de una política de vacunación universal hacia una vacunación selectiva
Authors: E Pi Salo
Journal: Eurosurveillance (2006)

En Finlandia hoy en dia se proporciona la vacuna BCG a todos los recien nacidos, y la cobertura vacunal es superior al 98%. La incidencia anual de la tuberculosis es escasa, de 6,6/100.000 en 2004, con una disminucion constante en los ultimos anos. En Finlandia, la diferencia con los otros paises nordicos es que la mayoria de los casos de tuberculosis se detectan en personas mayores de 65 anos nacidas en Finlandia, y una proporcion menor (12% de los casos) en inmigrantes. Aunque sea preocupante la alta incidencia de la TB y TB multirresistente en los paises vecinos, no se detecto aumento del numero de casos de TB en la poblacion nativa de Finlandia. Se ha decidido cambiar de la politica de vacunacion universal hacia una vacunacion diana para los grupos de riesgo.
Immune related adverse events (irAEs) in early phase immunotherapy (IO) trials: Implications for recommended phase 2 dose (RP2D) determination
Authors: Y. Kanjanapan, D. Day, M. Butler, L. Wang, A.M. Joshua, D. Hogg, N.B. Leighl, A.R.A. Razak, A.R. Hansen, S. Boujos, M.A. Chappell, K. Chow, M. Paolo, B. Sherwin, L-A. Stayner, L. Soultani, A. Zambrana, L.L. Siu, P.L. Bedard, A. Spreafico
Journal: Annals of Oncology (2017)
Optimizing Treatment for Cerebral Adrenoleukodystrophy in the Era of Gene Therapy
Authors: Marc Engelen
Journal: New England Journal of Medicine (2017)

Adrenoleukodystrophy is a peroxisomal metabolic disorder that can be manifested by rapidly progressive cerebral demyelination (known as cerebral adrenoleukodystrophy) in affected boys and men.1 Untreated cerebral adrenoleukodystrophy causes severe disability or death approximately 2 years after its onset.1 During the 1990s, it was established that stabilization of cerebral adrenoleukodystrophy lesions may occur 6 to 12 months after successful allogeneic hematopoietic stem-cell transplantation, and this is currently the only effective treatment.2,3 Only patients who have early-stage cerebral adrenoleukodystrophy at the time of diagnosis (with early-stage disease defined as a Loes score4 of 9 or less, with scores ranging from 0 to . . .
Comparison of Abiraterone Acetate and Docetaxel with Androgen Deprivation Therapy in High-risk and Metastatic Hormone-naïve Prostate Cancer: A Systematic Review and Network Meta-analysis
Authors: Christopher J.D. Wallis, Zachary Klaassen, Bimal Bhindi, Hanan Goldberg, Thenappan Chandrasekar, Ann M. Farrell, Stephen A. Boorjian, Girish S. Kulkarni, Robert Jeffrey Karnes, Raj Satkunasivam
Journal: European Urology (2017)
Clinical impact of molecular positive lymph node status in colorectal cancer
Authors: N. Matsuura, N. Tomita, M. Inomata, K. Murata, S. Hayashi, Y. Miyake, S. Igarashi, M. Itabashi, T. Kato, S. Noura, T. Furuhata, H. Ozawa, I. Takemasa, M. Yasui, H. Takeyama, O. Okamura, H. Yamamoto
Journal: Annals of Oncology (2017)
Efficacy of vemurafenib in patients (pts) with non-small cell lung cancer (NSCLC) with <i>BRAF</i><sup>V600</sup> mutation.
Authors: Vivek Subbiah, Radj Gervais, Gregory J. Riely, Antoine Hollebecque, Jean-Yves Blay, Enriqueta Felip, Martin H. Schuler, Anthony Goncalves, Antoine Italiano, Vicki Leigh Keedy, Ian Chau, Igor Puzanov, Noopur Raje, Martina Makrutzki, Todd Riehl, Bethany Pitcher, David Michael Hyman, Jose Baselga
Journal: Journal of Clinical Oncology (2017)

9074 Background: BRAF V600 mutations occur in 1–2% of pts with NSCLC. We previously reported the efficacy of vemurafenib, a selective BRAF V600 inhibitor, in BRAF mutation-positive non-melanoma tumors (VE-BASKET study). We now present final data for the expanded NSCLC cohort. Methods: This open-label, histology-independent, phase 2 study included 6 prespecified cohorts (including NSCLC) plus one ‘all-others’ cohort. Pts received vemurafenib (960 mg bid) until disease progression or unacceptable toxicity. The primary endpoint was objective response rate (RECIST v1.1). Secondary endpoints included best overall response rate, duration of response (DoR), progression-free survival (PFS), and overall survival (OS). Because the pre-specified clinical benefit endpoint was met in the initial NSCLC cohort, the cohort was expanded. ClinicalTrials.gov identifier NCT01524978. Results: Database lock was 12 Jan 2017. Of 208 pts enrolled at 25 centers worldwide, 62 pts had NSCLC: median age 65 years; 56% male; 13% had no prior systemic therapy; 50% had ≥2 prior therapies. Responses were seen in previously treated and untreated pts (Table). The most common all-grade adverse event (AE) was nausea (40%); grade 3–5 AEs included keratoacanthoma (15%) and squamous cell carcinoma of the skin (15%). Six pts discontinued vemurafenib due to AEs; two had non-treatment-related fatal AEs. Conclusions: Vemurafenib showed evidence of encouraging efficacy in pts with NSCLC with BRAF V600 mutation, with prolonged PFS in previously untreated pts; median OS was not estimable due to ongoing responses. The safety profile of vemurafenib was similar to that seen in melanoma studies. Our results suggest a role for BRAF inhibition in NSCLC with BRAF mutations. Clinical trial information: NCT01524978. [Table: see text]
Le réseau espagnol de surveillance de la tuberculose multirésistante
Authors: S Samper, M. J. Iglesias, O Tello
Journal: Eurosurveillance (2000)

Pres de 90% des laboratoires du systeme de sante national participent au reseau mis en place en Espagne en janvier 1998 pour evaluer, sur la base du typage genomique, la diffusion de la tuberculose multiresistante. Sur les 94 patients multiresistants dans l’etude de 1998, 30% etaient regroupes en clusters. Vingt pour cent des patients etaient co-infectes par le VIH, une proportion similaire a celle observee chez les patients sensibles. L’objectif du reseau est de creer au niveau national un systeme d’alerte precoce de la tuberculose multiresistante.
Tryptophan-Derived 3-Hydroxyanthranilic Acid Contributes to Angiotensin II–Induced Abdominal Aortic Aneurysm Formation in Mice In Vivo
Authors: Qiongxin Wang, Ye Ding, Ping Song, Huaiping Zhu, Imoh Okon, Yang-Nan Ding, Hou-Zao Chen, De-Pei Liu, Ming-Hui Zou
Journal: Circulation (2017)

Abnormal amino acid metabolism is associated with vascular disease. However, the causative link between dysregulated tryptophan metabolism and abdominal aortic aneurysm (AAA) is unknown.Indoleamine 2,3-dioxygenase (IDO) is the first and rate-limiting enzyme in the kynurenine pathway of tryptophan metabolism. Mice with deficiencies in both apolipoprotein e (Apoe) and IDO (Apoe-/-/IDO-/-) were generated by cross-breeding IDO-/- mice with Apoe-/- mice.The acute infusion of angiotensin II markedly increased the incidence of AAA in Apoe-/- mice, but not in Apoe-/-/IDO-/- mice, which presented decreased elastic lamina degradation and aortic expansion. These features were not altered by the reconstitution of bone marrow cells from IDO+/+ mice. Moreover, angiotensin II infusion instigated interferon-γ, which induced the expression of IDO and kynureninase and increased 3-hydroxyanthranilic acid (3-HAA) levels in the plasma and aortas of Apoe-/- mice, but not in IDO-/- mice. Both IDO and kynureninase controlled the production of 3-HAA in vascular smooth muscle cells. 3-HAA upregulated matrix metallopeptidase 2 via transcription factor nuclear factor-κB. Furthermore, kynureninase knockdown in mice restrained 3-HAA, matrix metallopeptidase 2, and resultant AAA formation by angiotensin II infusion. Intraperitoneal injections of 3-HAA into Apoe-/- and Apoe-/-/IDO-/- mice for 6 weeks increased the expression and activity of matrix metallopeptidase 2 in aortas without affecting metabolic parameters. Finally, human AAA samples had stronger staining with the antibodies against 3-HAA, IDO, and kynureninase than those in adjacent nonaneurysmal aortic sections of human AAA samples.These data define a previously undescribed causative role for 3-HAA, which is a product of tryptophan metabolism, in AAA formation. Furthermore, these findings suggest that 3-HAA reduction may be a new target for treating cardiovascular diseases.
Surveillance de la tuberculose en Europe
Authors: V Schwoebel, H. L. Rieder, J M Watson, M. C. Raviglione
Journal: Eurosurveillance (1996)

L'indicateur de morbidite de la tuberculose le plus informatif et le plus rapidement accessible est l'incidence de la maladie. En Europe, les differences de definitions des cas, de systemes de declaration et de collecte des informations entre les pays rendent difficiles les comparaisons (1,2) et genent l'analyse des tendances dans le temps, l'identification de groupes de population a haute incidence communs aux differents pays ainsi que la coordination internationale du controle de la tuberculose a l'echelon europeen.
Analysis of immunoregulatory biomarkers in early stages of non-small cell lung cancer
Authors: A. Moreno Manuel, S. Calabuig Fariñas, A. Herreros Pomares, S. Gallach Garcia, F. Aranda, A. Blasco, E. Carreras, F. Lozano, A. Cunquero Tomas, M. Martorell, E. Jantus-Lewintre, C. Camps Herrero
Journal: Annals of Oncology (2017)
The ELAN-ONCOVAL (ELderly heAd and Neck cancer-Oncology eValuation) study: Evaluation of the feasibility of a suited geriatric assessment for use by oncologists to classify patients as fit or unfit
Authors: C. Mertens, H. Le Caer, C. Ortholan, E. Blot, C. Even, H. Rousselot, F. Peyrade, C. Sire, D. Cupissol, Y. Pointreau, P. Debourdeau, F. Rolland, J. Fayette, O. Capitain, X. Sun, M. Debbah, D. Schwob, R. Boulahssass, A. Aupérin, J. Guigay
Journal: Annals of Oncology (2017)
GW28-e1131 Cellular Repressor of E1A-Stimulated Genes Protects from Myocardial Ischemia/Reperfusion Injury by Regulating Myocardial Autophagy and Apoptosis
Authors: Haixu Song, Chenghui Yan, Xiaoxiang Tian, Yang Li, Guitang Yang, Chengfei Peng, Mingyu Sun, Yaling Han, Wang Shuang
Journal: Journal of the American College of Cardiology (2017)